Detalles de la búsqueda
1.
Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy.
Haematologica
; 2024 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38721745
2.
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
Mol Cancer Ther
; 23(3): 368-380, 2024 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38052765
3.
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms.
bioRxiv
; 2023 Jan 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36711490
4.
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type.
Explor Target Antitumor Ther
; 2(6): 586-601, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-36046113
Resultados
1 -
4
de 4
1
Próxima >
>>